Geron to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN), a biopharmaceutical company, announced that CEO John A. Scarlett will present at the H.C. Wainwright BioConnect Conference. The pre-recorded presentation will be accessible starting at 7 a.m. ET on January 10, 2022, via a provided link and will be archived for 30 days post-event. Geron focuses on a first-in-class telomerase inhibitor, imetelstat, currently in two Phase 3 clinical trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference.

The pre-recorded company presentation will be available beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022 using the following link: https://journey.ct.events/view/0a8abdcd-614c-42a5-86d4-1b5902e19d32 and will also be available on the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104006038/en/

Olivia Bloom

Chief Financial Officer

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What is Geron Corporation's stock symbol?

Geron Corporation's stock symbol is GERN.

When will Geron present at the H.C. Wainwright BioConnect Conference?

Geron will present on January 10, 2022, starting at 7 a.m. ET.

How can I access Geron's conference presentation?

The presentation can be accessed via the link provided in the press release.

What clinical trials is Geron currently conducting?

Geron is conducting two Phase 3 clinical trials: IMerge and IMpactMF.

What is the focus of Geron Corporation?

Geron focuses on developing a first-in-class telomerase inhibitor for hematologic malignancies.